Osteoarthritis — an untreatable disease?

Osteoarthritis is a painful and disabling disease that affects millions of patients. Its aetiology is largely unknown, but is most likely multi-factorial. Osteoarthritis poses a dilemma: it often begins attacking different joint tissues long before middle age, but cannot be diagnosed until it becomes symptomatic decades later, at which point structural alterations are already quite advanced. In this review, osteoarthritis is considered as a disease of the whole joint that may result from multiple pathophysiological mechanisms, one of which is the dysregulation of lipid homeostasis. No proven disease-modifying therapy exists for osteoarthritis and current treatment options for chronic osteoarthritic pain are insufficient, but new pharmacotherapeutic options are emerging.

[1]  P. Cheras,et al.  Vascular mechanisms in osteoarthritis. , 2001, Best practice & research. Clinical rheumatology.

[2]  A. Yamaguchi,et al.  A human chondrogenic cell line retains multi-potency that differentiates into osteoblasts and adipocytes. , 2004, Bone.

[3]  D. Eyre,et al.  The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. , 2003, Arthritis and rheumatism.

[4]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Zien,et al.  Functional genomics of osteoarthritis. , 2002, Pharmacogenomics.

[6]  S. Petit-Zeman Characteristics of COX2 inhibitors questioned , 2004, Nature Reviews Drug Discovery.

[7]  J. Gimble,et al.  Bone and fat , 2004, Endocrine.

[8]  J. A. Cook,et al.  Neurogenic acceleration of osteoarthritis. , 1998, Current opinion in rheumatology.

[9]  P. Creamer Intra-articular corticosteroid treatment in osteoarthritis. , 2000, Current opinion in rheumatology.

[10]  S. Clarke,et al.  Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. , 2004, Arthritis and rheumatism.

[11]  L. Duong,et al.  The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. , 2004, Arthritis and rheumatism.

[12]  L. Sharma,et al.  Quadriceps Strength and Osteoarthritis Progression in Malaligned and Lax Knees , 2004, Annals of Internal Medicine.

[13]  Han,et al.  Specific NF‐κB blockade selectively inhibits tumour necrosis factor‐α‐induced COX‐2 but not constitutive COX‐1 gene expression in HT‐29 cells , 1998, Immunology.

[14]  Tomoyuki Saito,et al.  Distribution of Neuropeptides in Synovium of the Knee With Osteoarthritis , 2000, Clinical orthopaedics and related research.

[15]  L. Urbán,et al.  Mechanisms of inflammatory pain. , 2001, British journal of anaesthesia.

[16]  W. Zhang,et al.  A historic issue of the Annals: three papers examine paracetamol in osteoarthritis , 2004, Annals of the rheumatic diseases.

[17]  Adam Sapirstein,et al.  Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity , 2001, Nature.

[18]  S. Mazzuca,et al.  Quadriceps Weakness and Osteoarthritis of the Knee , 1997, Annals of Internal Medicine.

[19]  C. Woolf,et al.  Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α , 1997, British journal of pharmacology.

[20]  T McAlindon,et al.  Exercise for knee osteoarthritis , 2000, Current opinion in rheumatology.

[21]  E. Badley,et al.  Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. , 1998, The Journal of rheumatology.

[22]  M. Dougados,et al.  Intra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying , 2004, Annals of the Rheumatic Diseases.

[23]  G. Knutsen,et al.  Human articular chondrocytes express functional leptin receptors. , 2001, Biochemical and biophysical research communications.

[24]  M. Dougados,et al.  The use of glucosamine therapy in osteoarthritis , 2004, Current rheumatology reports.

[25]  Patricia Ducy,et al.  Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.

[26]  K. Brandt,et al.  Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? , 2000, Arthritis and rheumatism.

[27]  D. Loeuille,et al.  Evidence for a key role of leptin in osteoarthritis. , 2003, Arthritis and rheumatism.

[28]  J. Wallace,et al.  The therapeutic potential of NO‐NSAIDs , 2003, Fundamental & clinical pharmacology.

[29]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[30]  M. Hurley,et al.  Sensorimotor changes and functional performance in patients with knee osteoarthritis , 1997, Annals of the rheumatic diseases.

[31]  W. B. van den Berg,et al.  The relation between cartilage damage and osteophyte size in a murine model for osteoarthritis in the knee. , 1996, Rheumatology international.

[32]  Gerd Geisslinger,et al.  Specific Inhibition of IκB Kinase Reduces Hyperalgesia in Inflammatory and Neuropathic Pain Models in Rats , 2004, The Journal of Neuroscience.

[33]  B. Szebenyi,et al.  Hereditary disorders mimicking and/or causing premature osteoarthritis. , 2000, Bailliere's best practice & research. Clinical rheumatology.

[34]  P. Isakson,et al.  Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. , 1999, Mayo Clinic proceedings.

[35]  A. Parker,et al.  Expression profiling of metalloproteinases and their inhibitors in cartilage. , 2004, Arthritis and rheumatism.

[36]  Richard M Aspden,et al.  Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism , 2001, The Lancet.

[37]  H. Minehara,et al.  Growth Factor Expression in the Osteophytes of the Human Femoral Head in Osteoarthritis , 2000, Clinical orthopaedics and related research.

[38]  H. Schaible Mechanisms of pain in arthritis , 2002, Annals of the New York Academy of Sciences.

[39]  T. Schnitzer,et al.  A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. , 2004, Arthritis and rheumatism.

[40]  H Brenner,et al.  International variation in hip replacement rates , 2003, Annals of the rheumatic diseases.

[41]  J. Reginster,et al.  The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives , 2002 .

[42]  R. Flower The development of COX2 inhibitors , 2003, Nature Reviews Drug Discovery.

[43]  T. Spector,et al.  Risk factors for osteoarthritis: genetics. , 2004, Osteoarthritis and cartilage.

[44]  D. Felson,et al.  Osteoarthritis: is it a disease of cartilage or of bone? , 2004, Arthritis and rheumatism.

[45]  J. Magdalou,et al.  Evidence for the Presence of Peroxisome Proliferator-activated Receptor (PPAR) α and γ and Retinoid Z Receptor in Cartilage , 2000, The Journal of Biological Chemistry.

[46]  P. Halverson,et al.  Calcium crystal-induced inflammation. , 2001, Current opinion in rheumatology.

[47]  P. Tak,et al.  Chemokines in joint disease: the key to inflammation? , 2004 .

[48]  D. Lovinger,et al.  Disruption of Endocannabinoid Release and Striatal Long-Term Depression by Postsynaptic Blockade of Endocannabinoid Membrane Transport , 2004, The Journal of Neuroscience.

[49]  Y. Toda,et al.  Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. , 1998, The Journal of rheumatology.

[50]  S. Abramson,et al.  Inflammation in osteoarthritis. , 2004, The Journal of rheumatology. Supplement.

[51]  W. Buchanan,et al.  Osteoarthritis: symptoms, signs and source of pain , 2004, InflammoPharmacology.

[52]  P. Dieppe,et al.  Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. , 1996, The Journal of rheumatology.

[53]  C. Buckland-Wright Subchondral bone changes in hand and knee osteoarthritis detected by radiography. , 2004, Osteoarthritis and cartilage.

[54]  E. D. Harris The bone and joint decade: a catalyst for progress. , 2001, Arthritis and rheumatism.

[55]  J. Vane,et al.  Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.

[56]  S. Fuchs,et al.  Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. , 2004, Osteoarthritis and cartilage.

[57]  C. Woolf,et al.  Contribution of interleukin‐1β to the inflammation‐induced increase in nerve growth factor levels and inflammatory hyperalgesia , 1995, British journal of pharmacology.

[58]  J. Buckwalter,et al.  The burden of musculoskeletal conditions at the start of the new millennium , 2003 .

[59]  D. Walsh Angiogenesis in osteoarthritis and spondylosis: successful repair with undesirable outcomes , 2004, Current opinion in rheumatology.

[60]  M. Doherty,et al.  Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials , 2004, Annals of the rheumatic diseases.

[61]  P. Dieppe,et al.  Glucosamine for osteoarthritis: magic, hype, or confusion? , 2001, BMJ : British Medical Journal.

[62]  Pascal Richette,et al.  Peroxisome Proliferator-activated Receptor-γ Down-regulates Chondrocyte Matrix Metalloproteinase-1 via a Novel Composite Element* , 2004, Journal of Biological Chemistry.

[63]  R. Zernicke,et al.  Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[64]  J. Pelletier Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. , 2004, Osteoarthritis and cartilage.

[65]  J. Bolognese,et al.  A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. , 2000, Archives of internal medicine.

[66]  M. Kress,et al.  Involvement of the Proinflammatory Cytokines Tumor Necrosis Factor-α, IL-1β, and IL-6 But Not IL-8 in the Development of Heat Hyperalgesia: Effects on Heat-Evoked Calcitonin Gene-Related Peptide Release from Rat Skin , 2000, The Journal of Neuroscience.

[67]  E. Kunkel Systems biology in drug discovery , 2004, Nature Biotechnology.

[68]  A. Jeng,et al.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.

[69]  D. Felson,et al.  Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. , 2000, JAMA.

[70]  G. Firestein,et al.  Expression and Regulation of Inducible IκB Kinase (IKK-i) in Human Fibroblast-like Synoviocytes , 2001 .

[71]  Arndt F Schilling,et al.  Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.

[72]  R. Loeser Systemic and local regulation of articular cartilage metabolism: where does leptin fit in the puzzle? , 2003, Arthritis and rheumatism.

[73]  K. Brandt,et al.  Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. , 1999, The Journal of rheumatology.

[74]  L. Ryd,et al.  Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. , 1996, Annals of the rheumatic diseases.

[75]  Arden,et al.  EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) , 2003, Annals of the rheumatic diseases.

[76]  A. Freemont,et al.  Mast cells in the synovium and synovial fluid in osteoarthritis. , 1993, British journal of rheumatology.

[77]  C. Menkes,et al.  Are osteophytes good or bad? , 2004, Osteoarthritis and cartilage.

[78]  K. Mizumura Natural history of nociceptor sensitization: the search for a peripheral mechanism of hyperalgesia , 1998 .

[79]  Xiaoling Zhang,et al.  Suppression of early experimental osteoarthritis by gene transfer of interleukin‐1 receptor antagonist and interleukin‐10 , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[80]  K. Brune Safety of anti-inflammatory treatment--new ways of thinking. , 2004, Rheumatology.

[81]  Nih Consensus Panel NIH Consensus Statement on total knee replacement December 8-10, 2003. , 2004 .

[82]  W. B. van den Berg,et al.  Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. , 2003, Osteoarthritis and cartilage.

[83]  J. Vilensky,et al.  Peripheral and central nervous system mechanisms of joint protection. , 2003, American journal of orthopedics.

[84]  Leena Sharma,et al.  The influence of alignment on risk of knee osteoarthritis progression according to baseline stage of disease. , 2002, Arthritis and rheumatism.

[85]  A. Poole,et al.  Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. , 2003, Rheumatic diseases clinics of North America.

[86]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[87]  P. Richette,et al.  Structure-modifying agents for osteoarthritis: an update. , 2004, Joint, bone, spine : revue du rhumatisme.

[88]  K D Brandt,et al.  Osteophytes in osteoarthritis. Clinical aspects. , 1999, Osteoarthritis and cartilage.

[89]  Michael Doherty,et al.  Radiographic assessment of symptomatic knee osteoarthritis in the community: definitions and normal joint space , 1998, Annals of the rheumatic diseases.

[90]  Thomas Aigner,et al.  Articular cartilage and changes in Arthritis: Cell biology of osteoarthritis , 2001, Arthritis Research & Therapy.

[91]  R. Meyer,et al.  Pain and hyperalgesia after intradermal injection of bradykinin in humans , 1991, Clinical pharmacology and therapeutics.

[92]  D. Felson,et al.  Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. , 2003, JAMA.

[93]  D. Lajeunesse The role of bone in the treatment of osteoarthritis. , 2004, Osteoarthritis and cartilage.

[94]  T. Aigner,et al.  Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by osteogenic protein-1. , 2004, Clinical and experimental rheumatology.

[95]  F. Awiszus,et al.  Neuromuscular quadriceps dysfunction prior to osteoarthritis of the knee , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[96]  J. Levine,et al.  Mechanical sensitization of cutaneous C-fiber nociceptors by prostaglandin E2 in the rat , 1999, Neuroscience Letters.

[97]  Innovation OR Stagnation Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[98]  J. Pelletier,et al.  Cyclooxygenase-2 and prostaglandins in articular tissues. , 2003, Seminars in arthritis and rheumatism.

[99]  D. Walsh,et al.  Osteoarthritis, angiogenesis and inflammation. , 2005, Rheumatology.

[100]  D. Felson,et al.  Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. , 2000, The Journal of rheumatology.

[101]  M. Grynpas,et al.  Subchondral bone in osteoarthritis , 2007, Calcified Tissue International.

[102]  P. Tak,et al.  NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes. , 1999, Journal of immunology.

[103]  David T Felson,et al.  An update on the pathogenesis and epidemiology of osteoarthritis. , 2004, Radiologic clinics of North America.

[104]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[105]  D. Chadwick,et al.  Osteoarthritic joint pain , 2004 .

[106]  M. Dougados,et al.  Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. , 2002, Arthritis and rheumatism.

[107]  Tomohiro Kato,et al.  Neoantigens in osteoarthritic cartilage. , 2004, Current opinion in rheumatology.

[108]  J Dequeker,et al.  Inverse relationship osteoarthritis-osteoporosis: what is the evidence? What are the consequences? , 1996, British journal of rheumatology.

[109]  Cindy Farquhar,et al.  3 The Cochrane Library , 1996 .

[110]  M. Doherty,et al.  Public-access defibrillation and survival after out-of-hospital cardiac arrest* , 2004 .

[111]  P. Tak,et al.  NF-κB Regulation by IκB Kinase in Primary Fibroblast-Like Synoviocytes , 1999, The Journal of Immunology.

[112]  B. Whittle Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs. , 2004, Current opinion in pharmacology.

[113]  S. Lindblad,et al.  Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. , 1987, Arthritis and rheumatism.

[114]  X. Ayral Injections in the treatment of osteoarthritis. , 2001, Best practice & research. Clinical rheumatology.

[115]  J. Pelletier,et al.  15d-PGJ(2) is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes. , 2002, Osteoarthritis and cartilage.

[116]  L. A. Koman,et al.  Acute Pain Following Musculoskeletal Injuries and Orthopaedic Surgery , 2004 .

[117]  P. Mapp Innervation of the synovium. , 1995, Annals of the rheumatic diseases.

[118]  F. Berenbaum Signaling transduction: target in osteoarthritis , 2004, Current opinion in rheumatology.